The treatment known as LY-CoV555 was developed as part of a collaboration between Lilly and AbCellera Biologics Inc. of Vancouver.
The federal government has committed $ 175 million to AbCellera as it continues to rapidly develop, manufacture and distribute therapeutic antibodies.
AbCellera and Lilly announced in April a partnership to develop a new drug for the treatment and prevention of the COVID-19 virus, with Lilly exploiting the Vancouver biotechnology platform to target antibodies generated in a natural immune response to the coronavirus.
The goal is to develop a new drug to treat people infected with the virus.
The LY-CoV555 antibody treatment was developed over three months with the cooperation of the Vaccine Research Center of the National Institute of Allergies and Infectious Diseases after the organizations identified it from a blood sample taken from the one of the first American patients to recover from coronavirus. .
LY-CoV555 is the first potential new drug specifically designed to fight the virus that causes COVID-19.
The first patients were dosed at medical centers in the United States, including the NYU Grossman School of Medicine and Los Angeles’s Cedars-Sinai.
Lilly plans to review the study results later in June and continue with larger trials, while also starting large-scale manufacturing of the potential treatment.
“If LY-CoV555 is part of the short-term solution for COVID-19, we want to be ready to deliver it to patients as quickly as possible, with the goal of having several hundred thousand doses available by the end of the year, “Lilly scientific director Daniel Skovronsky said in a statement.
Learn more about Business In Vancouver